Iron Chelation
-
Surveys
TIF STUDY | Desferioxamine Usage Survey
Desferioxamine is crucial in managing iron overload for many patients with thalassaemia and related blood conditions. Recently, the Thalassaemia International Federation (TIF) has received growing reports of shortages in Desferioxamine,…
Read More » -
News
MYELODYSPLASTIC SYNDROMES | Advantages of Iron Chelation Revealed in Analysis of Low-Risk MDS
A recent groundbreaking study sheds new light on the effectiveness of iron chelation therapy (ICT) for patients suffering from low-risk myelodysplastic syndromes (LR-MDS). By delving into the impact of ICT…
Read More » -
News
NEWS | WHO Updates Essential Medicines List, Adds New Medicines for Thalassaemia
Until recently, the WHO EML recommended only deferoxamine for iron chelation, limiting patients’ access to other crucial pharmacological alternatives for the effective management of their condition. Since 2019, the Thalassaemia…
Read More » -
Webinars
eThalED COURSE: Current Care & New Advances in Iron Chelation by Dr. Farrukh Shah
TIF´s last webinar for the eThalED series for Medical Specialists on October 16, 2020, featured Dr Farrukh Shah, Consultant Haematologist, Whittington Hospital, London, UK, who reviewed all the current practices…
Read More »